crystal structure of Glycogen synthase kinase 3 in complexed with inhibitor

Experimental Data Snapshot

  • Resolution: 1.94 Å
  • R-Value Free: 0.242 
  • R-Value Work: 0.222 

wwPDB Validation   3D Report Full Report

This is version 1.3 of the entry. See complete history


Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418.

Bhat, R.Xue, Y.Berg, S.Hellberg, S.Ormo, M.Nilsson, Y.Radesater, A.C.Jerning, E.Markgren, P.O.Borgegard, T.Nylof, M.Gimenez-Cassina, A.Hernandez, F.Lucas, J.J.Diaz-Nido, J.Avila, J.

(2003) J Biol Chem 278: 45937-45945

  • DOI: https://doi.org/10.1074/jbc.M306268200
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 

    Glycogen synthase kinase 3 (GSK3) is a serine/threonine kinase that has been implicated in pathological conditions such as diabetes and Alzheimer's disease. We report the characterization of a GSK3 inhibitor, AR-A014418, which inhibits GSK3 (IC50 = 104 +/- 27 nM), in an ATP-competitive manner (Ki = 38 nM). AR-A014418 does not significantly inhibit cdk2 or cdk5 (IC50 > 100 microM) or 26 other kinases demonstrating high specificity for GSK3. We report the co-crystallization of AR-A014418 with the GSK3beta protein and provide a description of the interactions within the ATP pocket, as well as an understanding of the structural basis for the selectivity of AR-A014418. AR-A014418 inhibits tau phosphorylation at a GSK3-specific site (Ser-396) in cells stably expressing human four-repeat tau protein. AR-A014418 protects N2A neuroblastoma cells against cell death mediated by inhibition of the phosphatidylinositol 3-kinase/protein kinase B survival pathway. Furthermore, AR-A014418 inhibits neurodegeneration mediated by beta-amyloid peptide in hippocampal slices. AR-A014418 may thus have important applications as a tool to elucidate the role of GSK3 in cellular signaling and possibly in Alzheimer's disease. AR-A014418 is the first compound of a family of specific inhibitors of GSK3 that does not significantly inhibit closely related kinases such as cdk2 or cdk5.

  • Organizational Affiliation

    AstraZeneca R&D, 15185 Södertälje, Sweden, AstraZeneca R&D, 43183 Mölndal, Sweden. ratan.bhat@astrazeneca.com

Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Glycogen synthase kinase-3 beta
A, B
414Homo sapiensMutation(s): 0 
Gene Names: GSK3B
UniProt & NIH Common Fund Data Resources
Find proteins for P49841 (Homo sapiens)
Explore P49841 
Go to UniProtKB:  P49841
PHAROS:  P49841
GTEx:  ENSG00000082701 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP49841
Sequence Annotations
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
Query on TMU

Download Ideal Coordinates CCD File 
C [auth A],
D [auth B]
C12 H12 N4 O4 S
Binding Affinity Annotations 
IDSourceBinding Affinity
TMU BindingDB:  1Q5K Ki: min: 38, max: 770 (nM) from 2 assay(s)
IC50: min: 42, max: 3.30e+5 (nM) from 7 assay(s)
Binding MOAD:  1Q5K Ki: 38 (nM) from 1 assay(s)
PDBBind:  1Q5K Ki: 38 (nM) from 1 assay(s)
Experimental Data & Validation

Experimental Data

  • Resolution: 1.94 Å
  • R-Value Free: 0.242 
  • R-Value Work: 0.222 
  • Space Group: P 21 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 82.584α = 90
b = 84.913β = 90
c = 178.424γ = 90
Software Package:
Software NamePurpose
MOSFLMdata reduction
CCP4data scaling

Structure Validation

View Full Validation Report

Entry History 

Revision History  (Full details and data files)

  • Version 1.0: 2004-08-10
    Type: Initial release
  • Version 1.1: 2008-04-29
    Changes: Version format compliance
  • Version 1.2: 2011-07-13
    Changes: Version format compliance
  • Version 1.3: 2024-02-14
    Changes: Data collection, Database references, Derived calculations